Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

被引：0
|
作者：
Engert, Andreas [1 ]
Taylor, Fiona [2 ]
Bennett, Bryan [3 ]
Hirji, Ishan [4 ]
Cocks, Kim [3 ]
McDonald, Jeffrey [2 ]
Mann, Erin [2 ]
Kato, Kazunobu [4 ]
Cella, David [5 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Adelphi Values, Boston, MA USA
[3] Adelphi Values, Bollington, England
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] Northwestern Univ, Evanston, IL 60208 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1831.1831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1831
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study
    Engert, A.
    Domingo Domenech, E.
    Rueda, A.
    Armand, P.
    Trneny, M.
    Feldman, T.
    Ansell, S.
    Provencio, M.
    Jaeger, U.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sacchi, M.
    Sumbul, A.
    Ramchandren, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 273 - 273
  • [32] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Terui, Yasuhito
    Yamamoto, Kazuhito
    Fukuhara, Noriko
    Choi, Ilseung
    Kuroda, Junya
    Ando, Kiyoshi
    Hattori, Akira
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
  • [33] Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
    Carlo-Stella, Carmelo
    Collins, Graham P.
    Armand, Philippe
    Zinzani, Pier Luigi
    Cohen, Jonathon B.
    Halwani, Ahmad
    Millenson, Michael
    Provencio, Mariano
    Domingo Domenech, Eva
    Giulino-Roth, Lisa
    Castagna, Luca
    Kato, Kazunobu
    McKiver, Mihaela Popa
    Sumbul, Anne
    Zhu, Lili
    Trneny, Marek
    Minnema, Monique C.
    Rueda, Antonio
    Cunningham, David
    Reddy, Nishitha
    Younes, Anas
    Santoro, Armando
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S326 - S327
  • [34] Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
    Armand, Philippe
    Engert, Andreas
    Younes, Anas
    Lee, Hun Ju
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John M.
    Collins, Graham P.
    Ramchandren, Radhakrishnan
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Savage, Kerry J.
    Kuruvilla, John
    Trneny, Marek
    Shipp, Margaret A.
    Sacchi, Mariana
    Ansell, Anne Sumbuland Stephen M.
    Ansell, Stephen M.
    BLOOD, 2018, 132
  • [35] The Outcomes of Nivolumab Fixed Dose 40 Mg Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
    Fedorova, Liudmila
    Lepik, Kirill
    Kotselyabina, Polina
    Kondakova, Elena
    Zalyalov, Yuri
    Borzenkova, Evgeniya
    Baykov, Vadim
    Epifanovskaya, Olga S.
    Babenko, Elena V.
    Moiseev, Ivan S.
    Kulagin, Aleksander
    Mikhailova, Natalia
    Afanasyev, Boris
    BLOOD, 2020, 136
  • [36] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann-Grill, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    BLOOD, 2023, 142
  • [37] Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
  • [38] Neurocognitive, Psychosocial, and Quality-of-Life Outcomes in Adult Survivors of Childhood Non-Hodgkin Lymphoma
    Ehrhardt, Matthew J.
    Mulrooney, Daniel A.
    Li, Chenghong
    Baassiri, Malek J.
    Bjornard, Kari
    Sandlund, John T.
    Brinkman, Tara M.
    Huang, I-Chan
    Srivastava, Deo Kumar
    Ness, Kirsten K.
    Robison, Leslie L.
    Hudson, Melissa M.
    Krull, Kevin R.
    CANCER, 2018, 124 (02) : 417 - 425
  • [39] Nivolumab plus Doxorubicin, Vinblastine and Dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2-year follow-up results
    Engert, A.
    Domingo-Domenech, E.
    Ramchandren, R.
    Rueda, A.
    Trneny, M.
    Feldman, T.
    Lee, H. J.
    Provencio, M.
    Sillaber, C.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sumbul, A.
    Sacchi, M.
    Armand, P.
    Ansell, S. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 162 - 162
  • [40] Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
    Kasamon, Yvette L.
    Jacene, Heather A.
    Gocke, Christopher D.
    Swinnen, Lode J.
    Gladstone, Douglas E.
    Perkins, Brandy
    Link, Brian K.
    Popplewell, Leslie L.
    Habermann, Thomas M.
    Herman, Joseph M.
    Matsui, William H.
    Jones, Richard J.
    Ambinder, Richard F.
    BLOOD, 2012, 119 (18) : 4129 - 4132
12345